Technical Analysis for RLMD - Relmada Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | -4.36% | |
Oversold Stochastic | Weakness | -4.36% | |
Lower Bollinger Band Walk | Weakness | -5.63% | |
Inside Day | Range Contraction | -5.63% | |
Lower Bollinger Band Touch | Weakness | -5.63% | |
Oversold Stochastic | Weakness | -5.63% |
Alert | Time |
---|---|
Down 5% | about 18 hours ago |
60 Minute Opening Range Breakdown | about 20 hours ago |
1.5x Volume Pace | about 20 hours ago |
Down 3% | about 20 hours ago |
Fell Below Lower Bollinger Band | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.2225 |
52 Week Low | 1.88 |
Average Volume | 202,176 |
200-Day Moving Average | 3.80 |
50-Day Moving Average | 3.37 |
20-Day Moving Average | 3.32 |
10-Day Moving Average | 3.13 |
Average True Range | 0.22 |
RSI (14) | 25.93 |
ADX | 17.7 |
+DI | 12.45 |
-DI | 27.30 |
Chandelier Exit (Long, 3 ATRs) | 3.33 |
Chandelier Exit (Short, 3 ATRs) | 3.46 |
Upper Bollinger Bands | 3.77 |
Lower Bollinger Band | 2.87 |
Percent B (%b) | -0.02 |
BandWidth | 27.28 |
MACD Line | -0.12 |
MACD Signal Line | -0.06 |
MACD Histogram | -0.06 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.20 | ||||
Resistance 3 (R3) | 3.22 | 3.13 | 3.14 | ||
Resistance 2 (R2) | 3.13 | 3.04 | 3.12 | 3.12 | |
Resistance 1 (R1) | 2.99 | 2.99 | 2.95 | 2.97 | 3.10 |
Pivot Point | 2.90 | 2.90 | 2.88 | 2.89 | 2.90 |
Support 1 (S1) | 2.76 | 2.81 | 2.72 | 2.74 | 2.60 |
Support 2 (S2) | 2.67 | 2.76 | 2.66 | 2.58 | |
Support 3 (S3) | 2.53 | 2.67 | 2.56 | ||
Support 4 (S4) | 2.51 |